The 10-year global real-world data for Endurant™ stent graft system are now published in EJVES.1
Endurant™ and Endurant™ II/IIs stent graft system
The Endurant™ family of products has been chosen by physicians to treat more than 500,000 patients worldwide.2
As the first and only endovascular aneurysm repair (EVAR) system with a decade of global registry outcomes, Endurant™ systems continue to prove durability and strength in evidence with consistently high sac regression and low aneurysm-related mortality (ARM).2
Trials and registries |
Duration (years) |
N (total patients: 1,896) |
Endurant™ FIM study |
1 |
81 |
Endurant™ France post-market study |
5 |
180 |
de novo cohort of ENGAGE PAS (US) |
5 |
178 |
ENGAGE OUS registry full cohort |
5 |
1,263 |
ENGAGE OUS registry extended cohort |
10 |
390 |
Endurant™ US IDE study (AUI) |
5 |
44 |
| Endurant™ US IDE study (bifur) | 5 | 150 |
Trials and registries |
Trial study design |
Technical/deployment success (%)† |
Type I endoleak (%) |
Endurant™ FIM study3 |
Prospective, open-label, multicenter trial conducted at 10 sites across Germany and the Netherlands |
100 |
0 |
Endurant™ US IDE study (bifur)4 (N = 150) |
Prospective, multicenter trial conducted at 26 sites across the United States |
99.3 |
0 |
ENGAGE OUS registry5 |
Post-market, real-world registry involving 1,263 patients at 79 sites in 30 countries |
99.0 |
1.2 |
Outcomes from the Endurant™ US IDE study (bifur) |
At implant |
Successful delivery and deployment† |
99.3% |
Procedure duration (minutes) |
101.5 |
General anesthesia |
83.3% |
Blood loss (mL) |
185.8 |
ICU stay (hours) |
6.2 |
Hospital stay (days) |
2.1 |
Endurant™ is the first and only EVAR system with a decade of published global registry outcomes.
† Delivery success = successful vascular access and delivery of the device to the intended anatomical treatment site. Deployment success = successful deployment of the device in the intended site and the successful removal of the delivery system.
‡ Data reported through 10-year time frame with extended cohort.
§ Aneurysm-related re-interventions are defined as all the secondary endovascular procedures (scheduled and unscheduled), secondary vascular procedures and conversions to open repair.
◊ Data reported at 10-year time frame with extended cohort.
¶ Data reported through five-year time frame.
# Data reported at five-year time frame.
∆ Numbers are freedom from (FF) event survival estimate percent based on Kaplan-Meier method.
∞ Numbers are freedom from (FF) event survival estimate percent based on interval-censored method.
†† Data reported at one-year or five-year time frames.
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
